Alvopem (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance.

Background: Lung cancer is the leading cause of cancer deaths worldwide in both men and women, and non-small cell lung cancer (NSCLC) accounts for the majority (~ 85%) of lung cancers. This post-marketing surveillance (PMS) study aimed to evaluate the safety of Pemetrexed (Alvopem, NanoAlvand, Iran) in Iranian patients with lung cancer or mesothelioma.

Methods: The present study is an observational, single-center, open-label, and post-authorization study.